XM-ONE receives US patent protection

XM-ONE receives US patent protection

AbSorber, part of Allenex group, focusing on antibody detection before
transplantation has received US patent protection for its cross
match-test XM-ONE®.

The patent, with the title Methods of Donor Specific Crossmatching, was
granted by the US Patent and Trademark Office. AbSorber has previously
approved patent for XM-ONE® in other regions including the European
Union, India, Australia and Canada.

“The fact that our patent was approved in the U.S. is of great value to
us. It is a strong confirmation that the product is unique and has a
high degree of innovation. Currently we are working hard in
collaboration with leading laboratories in the U.S. to establish
clinical use of the product”, said Anders Karlsson, CEO Allenex.

XM-ONE®is unique in that it is the first standardized test that can
detect antibodies against the cells that line the inside of blood
vessels. These endothelial cells are the first point of contact between
the transplanted organ and the recipient's immune system.
Anti-endothelial cell antibodies have been shown to play a key role in
causing post-transplantation rejections. XM-ONE®is CE marked in the EU
and FDA cleared in the U.S.

Allenex AB discloses the information provided herein pursuant to the
Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 19:20 (CET) on October 12,
2011.

For more information please contact:
Anders Karlsson, CEO tel: +4670-918 0010, email:
anders.karlsson@allenex.se
Okee Williams, Portfolio & IR Manager tel: +4670-60 053 64, email:
okee.williams@allenex.se

Or visit www.allenex.se or www.absorber.se